RxDoctor Payments Data

Ya-Ting Chang, PA

Physician Assistant · Long Beach, CANPI 1801368014

Payments from drug & device makers

$1,494in general payments, 2019–2025

Across 44 payments — averaging $33.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$246
  • Gilead$236
  • Novo Nordisk$152
  • Amgen$148
  • Redhill Biopharma Inc.$137
  • Boehringer Ingelheim$96
  • plus $479 from 15 others

What the payments were for

  • Food & beverage$1,494100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,494 in reported general payments places this provider in the 75th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$14,076
Medicare patients
84
Services billed
166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin18$25,733
OzempicSemaglutide17$20,647
FarxigaDapagliflozin Propanediol14$17,243
JanuviaSitagliptin Phosphate15$17,186
EliquisApixaban18$13,988
Diclofenac Sodium13$5,199
DuleraMometasone/Formoterol14$3,632
Albuterol Sulfate HfaAlbuterol Sulfate55$1,310
Levothyroxine Sodium61$909
Omeprazole60$578
Atorvastatin Calcium57$571
Metformin Hcl54$491
Losartan Potassium41$449
Amlodipine Besylate86$442
Metoprolol Succinate25$311

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$96$25,73318 claims
Novo NordiskOzempic$152$20,64717 claims
AstraZenecaFarxiga$14$17,24314 claims
PfizerEliquis$18$13,98818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Long Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →